Sanofi is reported to be preparing a move to take control of US biotech Ocular Therapeutix, after an initial bid was rejected last year. That is according to French newspaper La Lettre, which said ...
Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics – a developer of in vivo cell therapies – for $1.5 billion in cash. Cambridge, Massachusetts-based Orbital is ...